Выбор лечения химиорефрактерного рака толстой кишки

Выбор лечения химиорефрактерного рака толстой кишки

Автор: Чепорова М.С., Чепоров С.В., Трякин А.А.

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Обзоры и аналитика

Статья в выпуске: 3 т.13, 2023 года.

Бесплатный доступ

Метастатический колоректальный рак (мКРР) представляет большую проблему в лечении злокачественных новообразований. Однако с развитием цитотоксической химиотерапии, таргетной терапии и локальных методов лечения, показатели выживаемости значительно улучшились. Лечение пациентов с КРР в третьей и последующих линиях терапии предлагает использование регорафениба/TAS-102, а также возврат к ранее использованной химиотерапии. Лечение на поздних линиях анти-EGFR антителами (цетуксимаб, панитумумаб) является предметом выбора при мКРР, так как демонстрирует повышение показателей выживаемости. При BRAF мутации комбинации, включающие ингибитор BRAF и анти-EGFR антитело, продемонстрировали свою эффективность во второй и последующих линиях. Особенностью амплификации HER2/neu является требование двойной блокады препаратами трастузумаб + лапатиниб или пертузумаб + трастузумаб (за исключением трастузумаба-дерукстекана). Для MSI-high высокоэффективна анти-PD терапия (ниволумаб, пембролизумаб или комбинированная терапия ниволумаб + ипилимумаб). Препараты адаграсиб и соторасиб продемонстрировали свою значимость при лечении КРР с мутацией KRAS G12C. Для NTRK-положительного колоректального рака одобрены два ингибитора - ларотректиниб и энтректиниб. Также стоит отметить, что одним из локальных вариантов лечения мКРР является стереотаксическая лучевая терапия. В данной статье представлены современные возможности терапии химиорезистентного КРР.

Еще

Колоректальный рак, прогрессирование, молекулярно-обоснованная терапия, таргетная терапия, иммунотерапия

Короткий адрес: https://sciup.org/140303412

IDR: 140303412   |   DOI: 10.18027/2224-5057-2023-13-3-56-63

Список литературы Выбор лечения химиорефрактерного рака толстой кишки

  • Margaret Byrne and Muhammad WasifSaif. Selecting treatment options in re-fractory metastatic colorectal cancer. Onco Targets Ther. 2019 ; Mar 27.12: 2271-2278. https://doi.org/10.2147/OTT.S194605.
  • D P Modest, S Pant, A Sartore-Bianchi. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer. 2019 Mar ; 109: 70-83. https://doi.org/10.1016/j.ejca.2018.12.019. Epub 2019 Jan 25.
  • Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 ; 27 (8): 1386-1422.
  • Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011 ; 129 (1): 245-255.
  • Grothey A, Van Cutsem E, et al. Lancet. 2013 ; 381 (9863): 303-312 ; 2. Li J, et al. Lancet Oncol. 2015 ; 16 (6): 619-629.
  • Федянин М. Ю., ПолянскаяЕ. М., ТрякинА. А. и др. Влияние стартовой дозы регорафениба на общую выживаемость пациентов с метастатическим раком толстой кишки: систематический обзор и метаанализ. Современная Онкология. 2019 ; 21 (3): 10-15. https://doi.org/10.26442/18151434.2019.3.190651.
  • John L Marshall, Fotios Loupakis, Tanios S Bekaii-Saab at al. Transitioning From Second-Line to Third-Line Therapy in Metastatic Colorectal Cancer. Clin Adv Hematol Oncol. 2021 Jan ; 19 Suppl 3 (1): 1-20.
  • JosepTabernero, Gerald W. Prager, Marwan Fakih et al. Trifluridine / tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study. https://doi.org/10.1200/JCO.2023.41.4_ suppl. 4 Journal of Clinical Oncology 41, no. 4_suppl (February 01, 2023) 4-4.
  • Jin Li, Shukui Qin, Rui-Hua Xu, Lin Shen et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colo-rectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018 Jun 26 ; 319 (24): 2486-2496. https://doi.org/10.1001/jama.2018.7855.
  • ToshikazuMoriwaki et al. Propensity Score Analysis of Regorafenib Versus Trifluridine / Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist. 2018 Jan ; 23 (1): 7-15. https://doi.org/10.1634/theoncologist.2017-0275. Epub 2017 Sep 11.
  • ChiaraCremolini. Trifluridine / Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. Oncologist. 2018 Oct ; 23 (10): 1178-1187. https://doi.org/10.1634/ theoncologist.2017-0573. Epub 2018 May 8.
  • Ana B K Abrahao, Yoo-JoungKo, Scott Berry, Kelvin K W Chan. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. Clin Colorectal Cancer. 2018 Jun ; 17 (2): 113-120. https://doi.org/10.1016/j.clcc.2017.10.016. Epub 2017 Nov 22.
  • Jianxin Chen, Junhui Wang, Hai Lin, Yonghai Peng. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials. Med Sci Monit. 2019 Dec 2 ; 25: 9179-9191. https://doi.org/10.12659/MSM.918411.
  • Ines De Pauw, Filip Lardon, Jolien Van den Bossche et al. Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. Cancers (Basel). 2019 Jan 15 ; 11 (1): 98. https://doi.org/10.3390/cancers11010098.
  • Sumita Trivedi et al. Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients. Clin Cancer Res. 2016 Nov 1 ; 22 (21): 5229-5237. 2016 May 23. https://doi.org/10.1158/1078-0432.CCR-15-2971.
  • Hecht J. R. et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 ; 110: 980-988.
  • Jonker D. J. et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007 ; 357: 2040-2048.
  • Timothy J Price, Marc Peeters, Tae Won Kim et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 meta-static colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May ; 15 (6): 569-79. https://doi.org/10.1016/S1470-2045(14)70118-4. Epub 2014 Apr 14.
  • Grothey A, Cutsem EV, Sobrero A, et al. CORRECT Study Group Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 ; 381 (9863): 303-312.
  • Moon Ki Choi, Yongjun Cha, Ji YeonBaek. Retreatment of Irinotecan in Later Lines of Therapy for Metastatic Colorectal Cancer: A Retrospective Study. Oncol-ogy. 2021 ; 99 (10): 665-672. https://doi.org/10.1159/000518041. Epub 2021 Aug 12.
  • Gianluca Mauri, Viviana Gori, Erica Bonazzina. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev. 2020 Dec ; 91: 102112. https://doi.org/10.1016/j.ctrv.2020.102112. Epub 2020 Oct 9.
  • ChiaraCremolini et al. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Front Oncol. 2023 Feb 2 ; 12: 946850. https://doi.org/10.3389/fonc.2022.946850. eCollection 2022.
  • Maria Alessandra Calegar et al. Chemotherapy rechallenge or reintroduction (CTr / r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study). May 26, 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl. 3556 Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 3556-3556.
  • OsmanKöstek et al. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Cancer Chemother Pharmacol. 2019 Jan ; 83 (1): 115-122. https://doi.org/10.1007/s00280-018- 3713-6. Epub 2018 Oct 29.
  • Gianluca Mauri, Erica Bonazzina, AlessioAmatu et al. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers (Basel). 2021 Jan 4 ; 13 (1): 137. https://doi.org/10.3390/cancers13010137.
  • М. Ю. Федянин, Х. М. Эльснукаева, И. А. Демидова, Д. Л. Строяковский идр. Колоректальный рак с мутацией в гене BRAF в Российской Федерации: эпидемиология и клинические особенности. Результаты многоцентрового исследования. Медицинский Совет. 2021 ; (4S): 52-63. https://doi.org/10.21518/2079-701X-2021-4S-52-63.
  • ScottKopetz et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 Feb 1 ; 39 (4): 285-294. https://doi.org/10.1200/JCO.20.01994. Epub 2020 Dec 23.
  • NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 1.2022 - February 25, 2022. NCCN. org.
  • MichelDucreux, Ali Chamseddine, Pierre Laurent-Puig et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. The Adv Med Oncol. 2019 Jun 18 ; 11: 1758835919856494. https://doi.org/10.1177/1758835919856494. eCollection 2019.
  • Andrea Sartore-Bianchi et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12 / 13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Jun ; 17 (6): 738-746. https://doi.org/10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20.
  • Strickler J, et al. Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. ESMO Congress 2022, LBA27.
  • FundaMeric-Bernstam et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 Apr ; 20 (4): 518-530. https://doi.org/10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8.
  • Ranju Gupta et al. Pertuzumab plus trastuzumab (P + T) in patients (Pts) with colorectal cancer (CRC) with ERBB2amplification or overexpression: Results from the TAPUR Study. February 04, 2020. https://doi.org/10.1200/JCO.2020.38.4_suppl. 132 Journal of Clinical Oncology 38, no. 4_suppl (February 01, 2020) 132-132.
  • Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021 Jun ; 22 (6): 779-789. https://doi.org/10.1016/S1470-2045(21)00086-3. Epub 2021 May 4.
  • Трякин А. А., Федянин М. Ю., Цуканов А. С., Шелыгин Ю. А., Покатаев И. А., Игнатова Е. О., Хакимова Г. Г., Фролова М. А., Тюляндин С. А. Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии. Злокачественные опухоли. 2019 ; 9 (4): 59-69. https://doi.org/10.18027/2224-5057-2019-9-4-59-69.
  • Dung T Le et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High / Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020 Jan 1 ; 38 (1): 11-19. https://doi.org/10.1200/JCO.19.02107. Epub 2019 Nov 14.
  • Xuan Zhang et al. Neoadjuvant Immunotherapy for MSI-H / dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Front Immunol. 2022 Mar 17 ; 13: 795972. https://doi.org/10.3389/fimmu.2022.795972. eCollection 2022.
  • Prete A. A. et al. Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study. J Clin Oncol. January 24, 2023. https://doi.org/10.1200/JCO.2023.41.4_ suppl. 218 Journal of Clinical Oncology 41, no. 4_suppl (February 01, 2023) 218-218.
  • Ardestani B. S. et al. Efficacy of pembrolizumab as first-line therapy in patients with mismatch repair-deficient metastatic colorectal cancer in relation to the metastatic site. J Clin Oncol. January 24, 2023. https://doi.org/10.1200/JCO.2023.41.4_suppl. 57 Journal of Clinical Oncology 41, no. 4_suppl (February 01, 2023) 57-57.
  • Stemmer A. et al. Predictive biomarkers for response to immunotherapy in patients with deficient DNA mismatch repair metastatic colorectal cancer. J Clin Oncol. January 24, 2023. https://doi.org/10.1200/JCO.2023.41.4_suppl. 254 Journal of Clinical Oncology 41, no. 4_suppl (February 01, 2023) 254-254.
  • Michael J Overman, Sara Lonardi. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient / Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 Mar 10 ; 36 (8): 773-779. https://doi.org/10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
  • Michael J Overman et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient / Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 Mar 10 ; 36 (8): 773-779. https://doi.org/10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
  • Rona Yaeger, Jared Weiss, Meredith S Pelster, Alexander I Spira et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5 ; 388 (1): 44-54. https://doi.org/10.1056/NEJMoa2212419. Epub 2022 Dec 21.
  • David S Hong, Marwan G Fakih, John H Strickler et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 Sep 24 ; 383 (13): 1207-1217. https://doi.org/10.1056/NEJMoa1917239. Epub 2020 Sep 20.
  • Marwan G Fakih et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022 Jan ; 23 (1): 115-124. https://doi.org/10.1016/S1470- 2045(21)00605-7. Epub 2021 Dec 15.
  • Y. Kuboki et al. Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016 / annonc / annonc1048. https://doi.org/10.1016/j.annonc.2022.10.077.
  • Garralda E, et al. Poster presentation at WCGI 2022: Abstract SO-31. 48. Ignacio Garrido-Laguna et al. EntrectinibinNTRKfusion-positive gastrointestinal cancers: updated integrated analysis. Annals of Oncology. V 33, Suppl 4, S370-S371, JUNE 2022. https://doi.org/10.1016/j.annonc.2022.04.431.
  • A Paix, D Antoni, R Adeduntan, G Noël. Stereotactic radiation therapy of brain metastases from colorectal cancer: A single institution cohort. Cancer Radiother. 2017 May ; 21 (3): 199-204. https://doi.org/10.1016/j.canrad. 2017.01.010. Epub 2017 May 9.
  • Christopher Cao et al. A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases. J Thorac Dis. 2019. Dec ; 11 (12): 5187-5198. https://doi.org/10.21037/jtd. 2019.12.12.
  • Naoko Sanuki. Role of stereotactic body radiotherapy in multidisciplinary management of liver metastases in patients with colorectal cancer. Jpn J Radiol. 2022 ; 40 (10): 1009-1016. 2022 Jul 20. https://doi.org/10.1007/s11604-022-01307-9.
Еще
Статья обзорная
SciUp 2024 © 2024 ©